Business Wire

CA-YUBICO

6.5.2024 15:01:34 CEST | Business Wire | Press release

Share
Yubico’s Key Product Innovations Empower Enterprise Security and Phishing-Resistant Passwordless Authentication at Scale

Today Yubico (NASDAQ: YUBICO), the leading provider of hardware authentication security keys, announced the upcoming release of YubiKey 5.7 firmware for the YubiKey 5 Series, Security Key Series and Security Key Series - Enterprise Edition. With a focus on enterprise needs, these updates reinforce Yubico’s commitment to providing secure, simple, and scalable authentication solutions. Security keys with firmware 5.7 will be available to purchase in late May 2024, offering enhanced features such as improved PIN complexity, enterprise attestation, and expanded passkey credentials storage. These updates empower organizations to adopt passwordless-first, modern authentication, fostering phishing-resistant users worldwide.

As part of Yubico’s goal of helping enterprises raise the bar for security with greater flexibility, the company also announced the availability of Yubico Authenticator 7 which will support the upcoming YubiKey 5.7 features.

“Organizations are continuing to face a surge in the variety and complexity of cyber threats at historical rates, often fueled by compromised employee login credentials, frequently resulting from attacks such as phishing. This trend is exacerbated by the rise in use of Artificial Intelligence (AI),” said Jeff Wallace, senior vice president of product at Yubico. “We’re excited to continue offering best-in-class solutions that protect organizations and accelerate their transition to passwordless with the latest enterprise-focused updates to the YubiKey. We’re confident that organizations are now better equipped than ever to enforce compliance requirements and elevate their security posture throughout their organization.”

YubiKey 5.7: Accelerating enterprises to passwordless

To help organizations tackle this challenge, Yubico’s key updates and enhancements to the YubiKey 5 Series and Security Key Series* include:

  • Enhanced PIN complexity across all YubiKey applications
    • Block simple patterns and common PINs at the hardware level to enable compliance with upcoming NIST requirements and corporate mandates. This includes FIDO2, PIV, and OpenPGP.
  • Enterprise attestation
    • Allow organizations to enforce the usage of YubiKeys that they purchased via custom programmed keys with enterprise attestation. Working in conjunction with identity providers, this capability can also facilitate the retrieval of unique identifiers during FIDO2 registration to streamline asset tracking and account recovery.
  • FIDO2 enhancements
    • Empower organizations to enforce compliance requirements and elevate security measures surrounding PIN usage. YubiKey 5.7 implements FIDO Client-to-Authenticator Protocol (CTAP) 2.1, embracing the latest FIDO2 protocol features such as Force PIN Change and Minimum PIN Length.
  • Expanded passkey and passwordless storage
    • Provide ample storage space to meet authentication needs while maintaining strong security standards. More storage for FIDO2 discoverable credentials (passkeys) and OATH one-time passwords will now accommodate up to 100 passkeys, 24 PIV certificates, 64 OATH seeds, and 2 OTP seeds at once for a total of 190 credentials.
  • Expansion and enhancement of public key algorithms for PIV applications
    • Align with DoD memo requirements and offer advanced key management functions, enhancing flexibility for organizations through support of larger RSA keys (RSA-3072 and RSA-4096), as well as Ed25519 and X25519 key types.
  • Migration to Yubico’s own cryptographic library
    • Yubico has developed a library in-house that performs the underlying cryptographic operations (decryption, signing, etc.) for RSA and ECC.

“The new features within 5.7 allow enterprises to streamline critical processes such as asset tracking and account recovery, while also enhancing flexibility,” said Wallace. “These updates empower enterprises with the latest authentication advancements and tools to build specific strategies for creating phishing-resistant users and mitigating phishing threats for employees, external identities, and customers.”

Capabilities in the new 5.7 YubiKeys also align with recent U.S. Government memo requirements on adopting phishing-resistant MFA and offer advanced key management functions. Compliance with upcoming NIST requirements and corporate mandates is also supported by enforcing the blocking of simple patterns and common PINs at the hardware level.

*Note: Smart Card/PIV capabilities, OATH and OTP credentials are not available on any Security Key Series thus these updates are not applicable. Enterprise attestation is available on the YubiKey 5 Series and Security Key Series - Enterprise Edition. See here for more details.

Yubico Authenticator 7: Hardware-backed authenticator app across desktop and mobile

Aligned with the 5.7 firmware release, significant updates within Yubico Authenticator 7 launched today in support of managing these new features. This new version enables use of the new public key algorithms for PIV, bringing more advanced management options and streamlines the interface for a better user experience when handling many credentials. Additionally, it adds localization with official support for French and Japanese, with additional community-provided translations. The app is now available for all major desktop platforms, as well as for Android. Enhanced features for iOS will be coming in the next version of the iOS application. It's the perfect companion to the new YubiKey 5.7, with its expanded credential storage.

The Yubico Authenticator delivers strong security by enabling users to store credentials on a YubiKey instead of a mobile phone, thereby significantly removing risks posed by remote attackers targeting software-based authenticator apps. By incorporating hardware-backed strong two-factor authentication in the YubiKey, credentials stays safe and the bar for security is raised while delivering the convenience of an authenticator app.

For more information on today’s innovation announcements from Yubico, visit here. To get the Yubico Authenticator 7 app, visit here.

About Yubico

Yubico (Nasdaq First North Growth Market Stockholm: YUBICO), the inventor of the YubiKey, offers the gold standard for phishing-resistant multi-factor authentication (MFA), stopping account takeovers in their tracks and making secure login easy and available for everyone. Since the company was founded in 2007, it has been a leader in setting global standards for secure access to computers, mobile devices, servers, browsers, and internet accounts. Yubico is a creator and core contributor to the FIDO2, WebAuthn, and FIDO Universal 2nd Factor (U2F) open authentication standards, and is a pioneer in delivering modern, hardware-based passkey authentication security at scale to customers in over 160 countries.

Yubico’s solutions enable passwordless logins using the most secure form of passkey technology. YubiKeys work out-of-the-box across hundreds of consumer and enterprise applications and services, delivering strong security with a fast and easy experience.

As part of its mission to make the internet more secure for everyone, Yubico donates YubiKeys to organizations helping at-risk individuals through the philanthropic initiative, Secure it Forward. The company is headquartered in Stockholm and Santa Clara, CA. For more information on Yubico, visit us at www.yubico.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506185894/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye